Treating castration-resistant, metastatic prostate cancer with rucaparib
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 1st, 2023
|
Rucaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) which can be used to suppress tumor cells. The PARP inhibitor disables the DNA repair mechanism that tumor cells used to survive. Thus, a study had been conducted to assess the effectiveness of Rucaparib in treating prostate cancers with mutations to either the BRCA or ATM genes.
The phase 3 randomized clinical trial was conducted on 405 patients who had been diagnosed with metastatic and castration-resistant prostate cancer with an alteration to either the BRCA gene or the ATM gene. These patients had previously been treated with a second-generation androgen-receptor pathway inhibitor. 270 of these patients were orally treated with 600 mg of rucaparib twice a day, and the other 135 were treated with a control treatment of either docetaxel, abiraterone acetate, or enzalutamide. After 62 months of treatment, the duration of progression-free survival was significantly longer in those treated with rucaparib than those treated with the control treatment. In the subgroup of patients with BRCA mutation, the progression-free duration in the rucaparib group is approximately 5 months longer, and the ATM subgroup was 1.5 months longer. In the rucaparib treatment group, the frequency of reported fatigue and nausea was significantly higher.
The phase 3 randomized clinical trial was conducted on 405 patients who had been diagnosed with metastatic and castration-resistant prostate cancer with an alteration to either the BRCA gene or the ATM gene. These patients had previously been treated with a second-generation androgen-receptor pathway inhibitor. 270 of these patients were orally treated with 600 mg of rucaparib twice a day, and the other 135 were treated with a control treatment of either docetaxel, abiraterone acetate, or enzalutamide. After 62 months of treatment, the duration of progression-free survival was significantly longer in those treated with rucaparib than those treated with the control treatment. In the subgroup of patients with BRCA mutation, the progression-free duration in the rucaparib group is approximately 5 months longer, and the ATM subgroup was 1.5 months longer. In the rucaparib treatment group, the frequency of reported fatigue and nausea was significantly higher.